Skip to main content

Advertisement

Table 2 Long-term exacerbation rate. Long-term (months 3–12) exacerbation rate in all patients, based on cut-points of ≥2, ≥6, and ≥10 reliever inhalations/day in the week preceding the 2-month visit

From: Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease

Mean reliever use (inhalations/day) Exacerbation ratea or ratio 95 % CI P-value
<2 0.596 (0.470, 0.756)  
2–5 0.724 (0.594, 0.882)  
6–9 0.996 (0.806, 1.230)  
≥10 1.403 (1.115, 1.766)  
2–5 versus <2 1.214 (0.891, 1.654) 0.22
6–9 versus <2 1.670 (1.215, 2.296) 0.0016
≥10 versus <2 2.353 (1.687, 3.282) <0.001
  1. CI confidence interval
  2. aRates are normalized for 10 months and expressed as events per year. Analysis adjusted for treatment effects